Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy
Public ClinicalTrials.gov record NCT06268665. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized Trial of Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy
Study identification
- NCT ID
- NCT06268665
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- University of California, Davis
- Other
- Enrollment
- 86 participants
Conditions and interventions
Conditions
- Breast Cancer
- Breast Cancer Invasive
- Breast Cancer Stage I
- Breast Cancer Stage II
- Breast Cancer Stage IIA
- Breast Cancer Stage IIB
- Breast Cancer Stage III
- Breast Cancer Stage IIIA
- Breast Cancer Stage IIIB
- Breast Cancer Stage IIIc
- Breast Cancer Stage IV
- Breast Cancer, Stage IA
- Breast Cancer, Stage IB
- Breast Carcinoma
- Breast Neoplasm
- Cancer of Ovary
- Cancer, Breast
- Invasive Breast Cancer
- Malignant Breast Neoplasm
- Malignant Tumor of Breast
- Mammary Cancer
- Mammary Carcinoma
- Ovarian Cancer
- Ovarian Cancer Stage 1
- Ovarian Cancer Stage 2
- Ovarian Cancer Stage 3
- Ovarian Cancer Stage IA
- Ovarian Cancer Stage IB
- Ovarian Cancer Stage IC
- Ovarian Cancer Stage II
- Ovarian Cancer Stage III
- Ovarian Cancer Stage IIIC
- Ovarian Cancer Stage IIIb
- Ovarian Cancer Stage IV
- Ovary Cancer
- Ovary Neoplasm
- Tumors, Breast
Interventions
- Tart Cherry Juice Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 14, 2024
- Primary completion
- Sep 30, 2027
- Completion
- Nov 30, 2027
- Last update posted
- Mar 3, 2026
2024 – 2027
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California Davis Comprehensive Cancer Center | Sacramento | California | 95827 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06268665, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 3, 2026 · Synced May 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06268665 live on ClinicalTrials.gov.